Antioxidants in Huntington's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 664-674

  Johri, Ashu ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antioxidant; Huntington's disease; PGC 1alpha

Indexed keywords

ACETYLCYSTEINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; APOCYNIN; ASCORBIC ACID; CARNITINE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; DNA; GRAPE SEED EXTRACT; HUNTINGTIN; IDEBENONE; LYCOPENE; MELATONIN; METALLOPORPHYRIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NORDIHYDROGUAIARETIC ACID; OLIVE OIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; SELENIUM; TACROLIMUS; TAUROURSODEOXYCHOLIC ACID; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG; WITHANIA SOMNIFERA EXTRACT;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CAG REPEAT; CELL DEATH; DISEASE COURSE; DISEASE SEVERITY; DNA FRAGMENTATION; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCITOTOXICITY; GAIN OF FUNCTION MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN UNFOLDING; REVIEW; STRIATONIGRAL DEGENERATION;

ANTIOXIDANTS; HUMANS; HUNTINGTON DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

MUS MUSCULUS;

EID: 84858159676     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.11.014     Document Type: Review

References (140)

1. Kovtun I.V., Liu Y., Bjoras M., Klungland A., Wilson S.H., McMurray C.T. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 2007, 447:447-452.
2. Nance M.A. Clinical aspects of CAG repeat diseases. Brain Pathol. 1997, 7:881-900.
3. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
4. Dunnett S.B., Rosser A.E. Cell therapy in Huntington's disease. NeuroRx 2004, 1:394-405.
5. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., Marder K., Penchaszadeh G., Roberts S.A., Gayan J., Brocklebank D., Cherny S.S., Cardon L.R., Gray J., Dlouhy S.R., Wiktorski S., Hodes M.E., Conneally P.M., Penney J.B., Gusella J., Cha J.H., Irizarry M., Rosas D., Hersch S., Hollingsworth Z., MacDonald M., Young A.B., Andresen J.M., Housman D.E., De Young M.M., Bonilla E., Stillings T., Negrette A., Snodgrass S.R., Martinez-Jaurrieta M.D., Ramos-Arroyo M.A., Bickham J., Ramos J.S., Marshall F., Shoulson I., Rey G.J., Feigin A., Arnheim N., Acevedo-Cruz A., Acosta L., Alvir J., Fischbeck K., Thompson L.M., Young A., Dure L., O'Brien C.J., Paulsen J., Brickman A., Krch D., Peery S., Hogarth P., Higgins D.S., Landwehrmeyer B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3498-3503.
6. Rosenblatt A., Liang K.Y., Zhou H., Abbott M.H., Gourley L.M., Margolis R.L., Brandt J., Ross C.A. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006, 66:1016-1020.
7. Hayden M.R., Kremer B. The Metabolic and Molecular Basis of Inherited Disease 2001, 5677-5701. McGraw-Hill, New York, USA. 8th ed. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
8. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
9. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5733-5737.
10. Albin R.L., Reiner A., Anderson K.D., Dure L.S.t., Handelin B., Balfour R., Whetsell W.O., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31:425-430.
11. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
12. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987, 411:162-166.
13. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
14. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 1997, 17:404-410.
15. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 2000, 26:300-306.
16. Reiner A., Dragatsis I., Zeitlin S., Goldowitz D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 2003, 28:259-276.
17. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
18. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 2001, 276:14545-14548.
19. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A., Boyce F.M., Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
20. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 2003, 28:425-433.
21. Velier J., Kim M., Schwarz C., Kim T.W., Sapp E., Chase K., Aronin N., DiFiglia M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 1998, 152:34-40.
22. Caviston J.P., Holzbaur E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19:147-155.
23. Godin J.D., Colombo K., Molina-Calavita M., Keryer G., Zala D., Charrin B.C., Dietrich P., Volvert M.L., Guillemot F., Dragatsis I., Bellaiche Y., Saudou F., Nguyen L., Humbert S. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
24. Sawa A., Nagata E., Sutcliffe S., Dulloor P., Cascio M.B., Ozeki Y., Roy S., Ross C.A., Snyder S.H. Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts. Neurobiol. Dis. 2005, 20:267-274.
25. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412:191-209.
26. Bae B.I., Hara M.R., Cascio M.B., Wellington C.L., Hayden M.R., Ross C.A., Ha H.C., Li X.J., Snyder S.H., Sawa A. Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3405-3409.
27. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
28. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
29. Palfi S., Brouillet E., Jarraya B., Bloch J., Jan C., Shin M., Conde F., Li X.J., Aebischer P., Hantraye P., Deglon N. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol. Ther. 2007, 15:1444-1451.
30. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S.U., Bredesen D.E., Tufaro F., Hayden M.R. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 1998, 18:150-154.
31. Miller J.P., Holcomb J., Al-Ramahi I., de Haro M., Gafni J., Zhang N., Kim E., Sanhueza M., Torcassi C., Kwak S., Botas J., Hughes R.E., Ellerby L.M. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010, 67:199-212.
32. Johri A., Beal M.F. Hunting-ton for new proteases: MMPs as the new target?. Neuron 2010, 67:171-173.
33. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., Surmeier D.J., Honig M.G., Carlock L.R., Reiner A. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 1999, 19:1189-1202.
34. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
35. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29:531-546.
36. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
37. Costa V., Giacomello M., Hudec R., Lopreiato R., Ermak G., Lim D., Malorni W., Davies K.J., Carafoli E., Scorrano L. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med. 2010, 2:490-503.
38. Song W., Chen J., Petrilli A., Liot G., Klinglmayr E., Zhou Y., Poquiz P., Tjong J., Pouladi M.A., Hayden M.R., Masliah E., Ellisman M., Rouiller I., Schwarzenbacher R., Bossy B., Perkins G., Bossy-Wetzel E. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 2011, 17:377-382.
39. Johri A., Chaturvedi R.K., Beal M.F. Hugging tight in Huntington's. Nat. Med. 2011, 17:245-246.
40. Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Reddy P.H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
41. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
42. Weydt P., Pineda V.V., Torrence A.E., Libby R.T., Satterfield T.F., Lazarowski E.R., Gilbert M.L., Morton G.J., Bammler T.K., Strand A.D., Cui L., Beyer R.P., Easley C.N., Smith A.C., Krainc D., Luquet S., Sweet I.R., Schwartz M.W., La Spada A.R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
43. McGill J.K., Beal M.F. PGC-1alpha, a new therapeutic target in Huntington's disease?. Cell 2006, 127:465-468.
44. Chaturvedi R.K., Adhihetty P., Shukla S., Hennessy T., Calingasan N., Yang L., Starkov A., Kiaei M., Cannella M., Sassone J., Ciammola A., Squitieri F., Beal M.F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 2009, 18:3048-3065.
45. Chaturvedi R.K., Calingasan N.Y., Yang L., Hennessey T., Johri A., Beal M.F. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet. 2010, 19:3190-3205.
46. Johri A., Starkov A.A., Chandra A., Hennessey T., Sharma A., Orobello S., Squitieri F., Yang L., Beal M.F. Truncated peroxisome proliferator-activated receptor-gamma coactivator 1alpha splice variant is severely altered in Huntington's disease. Neurodegener. Dis. 2011, 8:496-503.
47. Reddy P.H., Mao P., Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 2009, 61:33-48.
48. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 1999, Oxford University Press. 3rd ed. B. Halliwell, J.M.C. Gutteridge (Eds.).
49. Miller D.M., Buettner G.R., Aust S.D. Transition metals as catalysts of "autoxidation" reactions. Free Radic. Biol. Med. 1990, 8:95-108.
50. Cadenas E., Sies H. The lag phase. Free. Radic. Res. 1998, 28:601-609.
51. Kovacic P., Pozos R.S., Somanathan R., Shangari N., O'Brien P.J. Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Curr. Med. Chem. 2005, 12:2601-2623.
52. Muller F.L., Liu Y., Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J. Biol. Chem. 2004, 279:49064-49073.
53. Aikens J., Dix T.A. Perhydroxyl radical (HOO) initiated lipid peroxidation. The role of fatty acid hydroperoxides. J. Biol. Chem. 1991, 266:15091-15098.
54. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271:C1424-C1437.
55. Barja G. Free radicals and aging. Trends Neurosci. 2004, 27:595-600.
56. Boveris A. Biochemistry of free radicals: from electrons to tissues. Medicina (B Aires) 1998, 58:350-356.
57. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 2001, 52:159-164.
58. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
59. Hensley K., Robinson K.A., Gabbita S.P., Salsman S., Floyd R.A. Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med. 2000, 28:1456-1462.
60. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001, 52:3-6.
61. Jahani-Asl A., Cheung E.C., Neuspiel M., MacLaurin J.G., Fortin A., Park D.S., McBride H.M., Slack R.S. Mitofusin 2 protects cerebellar granule neurons against injury-induced cell death. J. Biol. Chem. 2007, 282:23788-23798.
62. Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Graber S., Kovacs I., Lee W.D., Waggoner J., Cui J., White A.D., Bossy B., Martinou J.C., Youle R.J., Lipton S.A., Ellisman M.H., Perkins G.A., Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006, 25:3900-3911.
63. Siems W.G., Grune T., Esterbauer H. 4-Hydroxynonenal formation during ischemia and reperfusion of rat small intestine. Life Sci. 1995, 57:785-789.
64. Stadtman E.R. Role of oxidant species in aging. Curr. Med. Chem. 2004, 11:1105-1112.
65. Montine T.J., Beal M.F., Robertson D., Cudkowicz M.E., Biaggioni I., O'Donnell H., Zackert W.E., Roberts L.J., Morrow J.D. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 1999, 52:1104-1105.
66. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 1999, 9:147-163.
67. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 2004, 5:373-384.
68. Stack E.C., Matson W.R., Ferrante R.J. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. N. Y. Acad. Sci. 2008, 1147:79-92.
69. Klepac N., Relja M., Klepac R., Hecimovic S., Babic T., Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J. Neurol. 2007, 254:1676-1683.
70. Sorolla M.A., Reverter-Branchat G., Tamarit J., Ferrer I., Ros J., Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 2008, 45:667-678.
71. Tasset I., Sanchez F., Tunez I. The molecular bases of Huntington's disease: the role played by oxidative stress. Rev. Neurol. 2009, 49:424-429.
72. Stoy N., Mackay G.M., Forrest C.M., Christofides J., Egerton M., Stone T.W., Darlington L.G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 2005, 93:611-623.
73. Chen C.M., Wu Y.R., Cheng M.L., Liu J.L., Lee Y.M., Lee P.W., Soong B.W., Chiu D.T. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 2007, 359:335-340.
74. Tunez I., Sanchez-Lopez F., Aguera E., Fernandez-Bolanos R., Sanchez F.M., Tasset-Cuevas I. Important role of oxidative stress biomarkers in Huntington's disease. J. Med. Chem. 2011, 54:5602-5606.
75. Braak H., Braak E. Allocortical involvement in Huntington's disease. Neuropathol. Appl. Neurobiol. 1992, 18:539-547.
76. Tellez-Nagel I., Johnson A.B., Terry R.D. Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol. 1974, 33:308-332.
77. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998, 87:49-53.
78. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 1995, 15:3775-3787.
79. Sorolla M.A., Rodriguez-Colman M.J., Tamarit J., Ortega Z., Lucas J.J., Ferrer I., Ros J., Cabiscol E. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic. Biol. Med. 2010, 49:612-621.
80. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 2008, 283:5780-5789.
81. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
82. Patel M., Day B.J., Crapo J.D., Fridovich I., McNamara J.O. Requirement for superoxide in excitotoxic cell death. Neuron 1996, 16:345-355.
83. Perluigi M., Poon H.F., Maragos W., Pierce W.M., Klein J.B., Calabrese V., Cini C., De Marco C., Butterfield D.A. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics 2005, 4:1849-1861.
84. Acevedo-Torres K., Berrios L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst) 2009, 8:126-136.
85. Stack C., Ho D., Wille E., Calingasan N.Y., Williams C., Liby K., Sporn M., Dumont M., Beal M.F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic. Biol. Med. 2010, 49:147-158.
86. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
87. Petersen A., Castilho R.F., Hansson O., Wieloch T., Brundin P. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res. 2000, 857:20-29.
88. Majewska M.D., Bell J.A. Ascorbic acid protects neurons from injury induced by glutamate and NMDA. Neuroreport 1990, 1:194-196.
89. Miyamoto M., Murphy T.H., Schnaar R.L., Coyle J.T. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J. Pharmacol. Exp. Ther. 1989, 250:1132-1140.
90. Wang J., Pfleger C.M., Friedman L., Vittorino R., Zhao W., Qian X., Conley L., Ho L., Pasinetti G.M. Potential application of grape derived polyphenols in Huntington's disease. Transl. Neurosci. 2010, 1:95-100.
91. Wang J., Ho L., Zhao W., Ono K., Rosensweig C., Chen L., Humala N., Teplow D.B., Pasinetti G.M. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:6388-6392.
92. Uz T., Giusti P., Franceschini D., Kharlamov A., Manev H. Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience 1996, 73:631-636.
93. Tunez I., Montilla P., Del Carmen Munoz M., Feijoo M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res. 2004, 37:252-256.
94. Santamaria A., Salvatierra-Sanchez R., Vazquez-Roman B., Santiago-Lopez D., Villeda-Hernandez J., Galvan-Arzate S., Jimenez-Capdeville M.E., Ali S.F. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J. Neurochem. 2003, 86:479-488.
95. Ryu J.K., Kim S.U., McLarnon J.G. Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. Exp. Neurol. 2003, 183:700-704.
96. Miyamoto M., Coyle J.T. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins. Exp. Neurol. 1990, 108:38-45.
97. Keene C.D., Rodrigues C.M., Eich T., Linehan-Stieers C., Abt A., Kren B.T., Steer C.J., Low W.C. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp. Neurol. 2001, 171:351-360.
98. Fontaine M.A., Geddes J.W., Banks A., Butterfield D.A. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J. Neurochem. 2000, 75:1709-1715.
99. Lawler J.M., Barnes W.S., Wu G., Song W., Demaree S. Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 2002, 290:47-52.
100. O'Gorman E., Beutner G., Dolder M., Koretsky A.P., Brdiczka D., Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997, 414:253-257.
101. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 1998, 18:156-163.
102. Shear D.A., Haik K.L., Dunbar G.L. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 2000, 11:1833-1837.
103. Beal M.F., Henshaw D.R., Jenkins B.G., Rosen B.R., Schulz J.B. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 1994, 36:882-888.
104. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8892-8897.
105. Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante R.J., Beal M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109:1427-1439.
106. Kumar P., Kalonia H., Kumar A. Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain. Drug Chem. Toxicol. 2010, 33:377-392.
107. Kumar P., Kumar A. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem. Toxicol. 2009, 47:2522-2530.
108. Yang L., Calingasan N.Y., Thomas B., Chaturvedi R.K., Kiaei M., Wille E.J., Liby K.T., Williams C., Royce D., Risingsong R., Musiek E.S., Morrow J.D., Sporn M., Beal M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009, 4:e5757.
109. Packer L., Tritschler H.J., Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic. Biol. Med. 1997, 22:359-378.
110. Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 2009, 1790:1149-1160.
111. Andreassen O.A., Ferrante R.J., Dedeoglu A., Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 2001, 12:3371-3373.
112. Andreassen O.A., Ferrante R.J., Huang H.M., Dedeoglu A., Park L., Ferrante K.L., Kwon J., Borchelt D.R., Ross C.A., Gibson G.E., Beal M.F. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 2001, 50:112-117.
113. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.E., Beal M.F. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J. Neurochem. 2003, 86:267-272.
114. Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10671-10676.
115. Tarnopolsky M.A., Beal M.F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 2001, 49:561-574.
116. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
117. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
118. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
119. Vamos E., Voros K., Vecsei L., Klivenyi P. Neuroprotective effects of l-carnitine in a transgenic animal model of Huntington's disease. Biomed. Pharmacother. 2010, 64:282-286.
120. Beal M.F., Matson W.R., Storey E., Milbury P., Ryan E.A., Ogawa T., Bird E.D. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 1992, 108:80-87.
121. Campesan S., Green E.W., Breda C., Sathyasaikumar K.V., Muchowski P.J., Schwarcz R., Kyriacou C.P., Giorgini F. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 2011, 21:961-966.
122. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.
123. Peyser C.E., Folstein M., Chase G.A., Starkstein S., Brandt J., Cockrell J.R., Bylsma F., Coyle J.T., McHugh P.R., Folstein S.E. Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry 1995, 152:1771-1775.
124. Ranen N.G., Peyser C.E., Coyle J.T., Bylsma F.W., Sherr M., Day L., Folstein M.F., Brandt J., Ross C.A., Folstein S.E. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 1996, 11:549-554.
125. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R., Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
126. Beal M.F. Neuroprotective effects of creatine. Amino Acids 2011, 40:1305-1313.
127. Hyson H.C., Kieburtz K., Shoulson I., McDermott M., Ravina B., de Blieck E.A., Cudkowicz M.E., Ferrante R.J., Como P., Frank S., Zimmerman C., Ferrante K., Newhall K., Jennings D., Kelsey T., Walker F., Hunt V., Daigneault S., Goldstein M., Weber J., Watts A., Beal M.F., Browne S.E., Metakis L.J. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov. Disord. 2010, 25:1924-1928. Huntington Study Group, Pre2CARE InvestigatorsPre2CARE Investigators.
128. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jager S., Handschin C., Zheng K., Lin J., Yang W., Simon D.K., Bachoo R., Spiegelman B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
129. Leone T.C., Lehman J.J., Finck B.N., Schaeffer P.J., Wende A.R., Boudina S., Courtois M., Wozniak D.F., Sambandam N., Bernal-Mizrachi C., Chen Z., Holloszy J.O., Medeiros D.M., Schmidt R.E., Saffitz J.E., Abel E.D., Semenkovich C.F., Kelly D.P. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005, 3:e101.
130. Lin J., Wu P.H., Tarr P.T., Lindenberg K.S., St-Pierre J., Zhang C.Y., Mootha V.K., Jager S., Vianna C.R., Reznick R.M., Cui L., Manieri M., Donovan M.X., Wu Z., Cooper M.P., Fan M.C., Rohas L.M., Zavacki A.M., Cinti S., Shulman G.I., Lowell B.B., Krainc D., Spiegelman B.M. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004, 119:121-135.
131. Kalonia H., Kumar P., Kumar A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav. 2010, 96:115-124.
132. Chiang M.C., Chen C.M., Lee M.R., Chen H.W., Chen H.M., Wu Y.S., Hung C.H., Kang J.J., Chang C.P., Chang C., Wu Y.R., Tsai Y.S., Chern Y. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet. 2010, 19:4043-4058.
133. Kasparova S., Sumbalova Z., Bystricky P., Kucharska J., Liptaj T., Mlynarik V., Gvozdjakova A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 2006, 48:93-99.
134. Kalonia H., Kumar P., Kumar A. Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats. Eur. J. Pharmacol. 2010, 634:46-52.
135. Goety C.G., Tanner C.M., Cohen J.A., Thelen J.A., Carroll V.S., Klawans H.L., Fariello R.G. l-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov. Disord. 1990, 5:263-265.
136. Maldonado P.D., Molina-Jijon E., Villeda-Hernandez J., Galvan-Arzate S., Santamaria A., Pedraza-Chaverri J. NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin. J. Neurosci. Res. 2010, 88:620-629.
137. Lee J., Kosaras B., Del Signore S.J., Cormier K., McKee A., Ratan R.R., Kowall N.W., Ryu H. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol. 2011, 121:487-498.
138. Tasset I., Pontes A.J., Hinojosa A.J., de la Torre R., Tunez I. Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model. Nutr. Neurosci. 2011, 14:106-111.
139. Ryu J.K., Choi H.B., McLarnon J.G. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006, 141:1835-1848.
140. Kumar P., Kumar A. Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. J. Med. Food 2009, 12:591-600.